Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12428542

Beta-agonists.

Ellen J Dutta·James T C Li
View original source ↗Export metadata ↓

Abstract

Beta-Agonists are a mainstay of asthma treatment. Short-acting beta-agonists are the most effective bronchodilators for rescue or quick relief of symptoms. Long-acting beta-agonists have a key role in long-term control when added to inhaled corticosteroid therapy, and are especially useful in the control of nocturnal asthma. Both types of beta-agonists may be used in the prophylaxis of exercise-induced asthma with long-acting beta-agonists providing more prolonged protection. beta-Agonists have minimal side effects and are safe when used appropriately.

Explore related subjects

Adrenergic beta-AgonistsAsthmaHumansJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ellen J Dutta, James T C Li. 2002. Beta-agonists.. https://doi.org/10.1016/s0025-7125(02)00031-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms.

Treatment with lipopolysaccharide (LPS) for 72 h was shown to dose-dependently increase nitric oxide production from 6-day-old retinal cultures. Cell death, as determined by lactate dehydrogenase (LDH) release and an increase in neuronal labelling for TUNEL, was elevated concurrently. During treatment there was an increase of both inducible nitric oxide synthase and glial fibrillary acidic protein labelling in glial cells and a reduction in the number of gamma-aminobutyric acid-positive neurones. The NOS inhibitors, N-nitro-L-arginine methyl ester, dexamethasone and indomethacin potently inhibited both nitric oxide stimulation and cell death caused by LPS. In this study, the beta(2)- (ICI-18551), beta(1)- (betaxolol) and mixed beta(1)/beta(2)- (timolol, metipranolol) adrenergic receptor antagonists were all shown to attenuate LPS-induced LDH release from these cultures, but to have no effect on LPS-stimulated nitric oxide production. This effect was mimicked by the calcium channel blocker, nifedipine. Interestingly, the beta-adrenergic receptor agonists, salbutamol, arterenol and isoproterenol were also able to attenuate cell death caused by LPS. Moreover, these compounds also inhibited LPS-stimulated nitric oxide release. These studies suggest that LPS stimulates nitric oxide release from cultured retinal glial cells and that this process leads to neurone death. beta-adrenergic receptor agonists prevent the effects of LPS by inhibiting the stimulation of nitric oxide production. The data also suggest that beta-adrenergic receptor antagonists can attenuate LPS-induced death of neurones, but that these compounds act in a manner that is neurone-dependent, is mimicked by blockade of calcium channels and is independent of the stimulation of nitric oxide release.

Adrenergic beta-Agonists↗
PubMed2003

H89, an inhibitor of protein kinase A (PKA), stimulates Na+ transport by translocating an epithelial Na+ channel (ENaC) in fetal rat alveolar type II epithelium.

The present study was performed to clarify the effect of H89, an inhibitor of cAMP-activated protein kinase (protein kinase A; PKA), on Na(+) absorption in fetal rat alveolar type II epithelium. H89 stimulated the Na(+) absorption by increasing the open probability (Po) and number of a nonselective cation (NSC) channel composed of four alpha subunits of epithelial Na(+) channel (ENaC). Brefeldin A (BFA), an inhibitor of intracellular protein translocation, blocked the stimulatory action of H89 on the Na(+) absorption by interrupting the action of H89 on the Po and number of the NSC channel. H85, an inactive form of H89, showed an effect similar to H89, suggesting that H89 does not show its effect by inhibiting PKA, but acts on the channel depending the structure. These observations indicate that: (1) the H89 induced increase in number of the channel at the apical membrane is due to translocation of alpha subunit of ENaC to the apical membrane, (2) the elevation of Po of the channel is mediated through translocation of a protein activating alpha subunit of ENaC, and (3) the effect of H89 is dependent on its structure without any relation to PKA.

Adrenergic beta-Agonists↗
PubMed2003

HPLC determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in compound dosage forms with an aqueous-organic mobile phase.

A high-performance liquid chromatography procedure for the simultaneous determination of aminophylline, methoxyphenamine hydrochloride, noscapine and chlorphenamine maleate in commercially available compound capsule dosage forms has been developed and validated. The separation and quantification were achieved on an Ultrasphere C18 column using a mobile phase of dichloromethane-methanol-0.25% (v/v) diethylamine aqueous solution (20:60:20, v/v/v) at a flow rate of 1 ml min(-1) with detection of all analytes at 264 nm. The separation was achieved within 6 min for each drug mixture. The method showed good linearity for the aminophylline, noscapine, chlorphenamine maleate and methoxyphenamine hydrochloride mixture in the 125-750, 35-210, 10-60 and 62.5-375 microg ml(-1) ranges, respectively. The intra- and inter-day R.S.D.s ranged from 0.4 to 0.5%, 0.4-0.6%, 0.5-0.7% and 0.4-0.6% for aminophylline, noscapine, chlorphenamine maleate and methoxyphenamine hydrochloride, respectively. The recoveries (mean+/-S.D.) of low, middle and high concentrations were 99.9+/-0.9, 100.4+/-1.3 and 99.7+/-0.7% for aminophylline; 99.9+/-1.1, 100.4+/-0.7 and 100.1+/-0.8% for noscapine; 99.8+/-1.1, 99.7+/-1.0 and 100.7+/-0.8% for chlorphenamine maleate; and 99.8+/-0.9, 100.4+/-1.6 and 99.9+/-0.9% for methoxyphenamine hydrochloride, respectively.

Adrenergic beta-Agonists↗